MetaCap

Apimeds Pharmaceuticals US Earnings

NYSE: APUSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.60-0.14 (-8.05%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Apimeds Pharmaceuticals US earnings summary

In its most recent report on Nov 16, 2026 (Sep/2026), APUS posted EPS of $0.29. Across the last 6 reports, APUS shares moved an average of 15.6% (in either direction) in the first trading session after results, rising 1 times and falling 5 times.

Summary generated from market data by MetaCap's automated system. Methodology

APUS earnings history

Apimeds Pharmaceuticals US reported EPS versus estimates
Report dateEPS est.EPS actualSurprisePrice reaction
Nov 16, 2026—$0.29——
Nov 11, 2026—$-1.40—-28.3%
Aug 14, 2026—$-11.77—+6.4%
May 26, 2026—$-2.26—-9.9%
Nov 12, 2025—$-1.42—-29.0%
Aug 19, 2025—$-2.57—-16.8%
May 20, 2025—$-0.05—-3.3%

Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.

Related